To explore the clinical effect of Qisheng Gushen Decoction(芪参固肾汤)combined with irbesartan in the treatment of chronic kidney disease at stage 2~3.
A total of 110 patients with chronic kidney disease at stage 2~3(admitted from August 2021 to October 2023)were divided into decoction group and western medicine group by random number table method,with 55 cases in each group.The western medicine group received irbesartan and other western medicines,and the decoction group was treated with Qisheng Gushen Decoction on the basis of the western medicine group.In the course of treatment,1 case was shed in the western medicine group and 2 cases were shed in the decoction group.The data of each group was observed as follows:curative effect,integral changes of TCM symptoms(main disease and secondary disease)before and after treatment,changes of renal function indicators,changes of inflammatory factors indicators,changes of intestinal flora,changes of T lymphocyte subsets and other immune function indicators,adverse reactions.
The total effective rate of the decoction group was significantly higher than that of the western medicine group(P<0.05).After treatment,the scores of TCM syndrome(main disease and secondary disease),24-hour urinary protein quantification(24 h-UTP),serum creatinine(SCr),urea nitrogen(BUN),albumin(ALB),estimated glomerular filtration rate(eGFR),interleukin-6(IL-6),interleukin-17(IL-17)and hypersensitive C-reactive protein(hs-CRP),intestinal flora indicators such as Lactobacillus acidophilus,bifidobacterium and Escherichia coli,and immune indicators such as T lymphocyte subsets(CD3+,CD4+,CD8+,CD4+/CD8+)were improved.In the decoction group,these indexes were all better than those in western medicine group(P<0.05).The total adverse reaction rate of the decoction group was lower than that of the western medicine group(P<0.05).
Qisheng Gushen Decoction combined with irbesartan in the treatment of chronic kidney disease at stage 2~3 can regulate the immune function,improve the renal function,immune function and inflammatory response of patients,enhance the therapeutic effect,and reduce adverse reactions,and the treatment is safe and reliable.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |